EPTINEZUMAB FOR PREVENTION OF CHRONIC MIGRAINE (CM): RESULTS OF 2 INFUSIONS IN THE PHASE 3 PROMISE-2 (PREVENTION OF MIGRAINE VIA INTRAVENOUS EPTINEZUMAB SAFETY AND EFFICACY-2) TRIAL

被引：0
|
作者：
Ashina, M. [1 ]
Goadsby, P. J. [2 ]
Lipton, R. B. [3 ]
Azimova, J. [4 ]
Winner, P. [5 ]
Schaeffler, B. [6 ]
Biondi, D. [6 ]
Bhattacharya, S. [6 ]
Smith, J. [7 ]
Cady, R. [6 ]
机构：
[1] Univ Copenhagen, Rigshosp Glostrup, Danish Headache Ctr, Copenhagen, Denmark
[2] Kings Coll London, NIHR Wellcome Trust Kings Clin Res Facil, London, England
[3] Albert Einstein Coll Med, Montefiore Headache Ctr, Bronx, NY 10467 USA
[4] Univ Headache Clin, Moscow, Russia
[5] Palm Beach Headache Ctr, Premiere Res Inst, W Palm Beach, FL USA
[6] Alder BioPharmaceut Inc, Bothell, WA USA
[7] Alder BioPharmaceut Inc, Dublin, Ireland
来源：
CEPHALALGIA | 2018年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS2018-0
引用
收藏
页码：84 / 85
页数：2
相关论文
共 50 条
  • [1] Eptinezumab for Prevention of Chronic migraine: Results of 2 Infusions in the Phase 3 PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) Trial
    Kudrow, David
    Lipton, Richard
    Silberstein, Stephen
    Cady, Roger
    Schaeffler, Barbara
    Biondi, David
    Smith, Jeff
    NEUROLOGY, 2019, 92 (15)
  • [2] Eptinezumab for Prevention of Chronic Migraine (CM): Results of 2 Quarterly Intravenous Infusions in the Phase 3 PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and efficacy-2) Trial
    Lipton, R. B.
    Goadsby, P. J.
    Azimova, J.
    Ashina, M.
    Spierings, E. L. H.
    Winner, P. K.
    Schaeffler, B.
    Biondi, D.
    Bhattacharya, S.
    Smith, J.
    Cady, R.
    HEADACHE, 2018, 58 (08): : 1300 - 1300
  • [3] A Phase 3 Study to Evaluate Eptinezumab for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) Trial
    Lipton, R. B.
    Saper, J.
    Ashina, M.
    Biondi, D.
    Bhattacharya, S.
    Hirman, J.
    Schaeffler, B.
    Cady, R.
    HEADACHE, 2018, 58 : 80 - 80
  • [4] Eptinezumab Achieved Meaningful Reductions in Migraine Activity as Early as Day 1: PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) Phase 3 Trial in Chronic Migraine
    Kudrow, D.
    Diamond, M.
    McGill, L.
    Cady, R.
    Bhattacharya, S.
    Biondi, D.
    Hirman, J.
    Smith, J.
    HEADACHE, 2018, 58 : 74 - 74
  • [5] Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study
    Silberstein, Stephen
    Diamond, Merle
    Hindiyeh, Nada A.
    Biondi, David M.
    Cady, Roger
    Hirman, Joe
    Allan, Brent
    Pederson, Susan
    Schaeffler, Barbara
    Smith, Jeff
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [6] Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
    Lipton, Richard B.
    Goadsby, Peter J.
    Smith, Jeff
    Schaeffler, Barbara A.
    Biondi, David M.
    Hirman, Joe
    Pederson, Susan
    Allan, Brent
    Cady, Roger
    NEUROLOGY, 2020, 94 (13) : E1365 - E1377
  • [7] Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
    Stephen Silberstein
    Merle Diamond
    Nada A. Hindiyeh
    David M. Biondi
    Roger Cady
    Joe Hirman
    Brent Allan
    Susan Pederson
    Barbara Schaeffler
    Jeff Smith
    The Journal of Headache and Pain, 2020, 21
  • [8] EPTINEZUMAB RESULTS FOR THE PREVENTION OF EPISODIC MIGRAINE THROUGH 1 YEAR IN THE PHASE 3 PROMISE-1 (PREVENTION OF MIGRAINE VIA INTRAVENOUS EPTINEZUMAB SAFETY AND EFFICACY-1) TRIAL
    Dodick, D.
    Janelidze, M.
    Saper, J.
    Kudrow, D.
    Chakhava, G.
    Schaeffler, B.
    Cady, R.
    Hirman, J.
    Smith, J.
    CEPHALALGIA, 2018, 38 : 89 - 90
  • [9] Eptinezumab Results for the Prevention of Episodic Migraine over One Year in the PROMISE-1 (PRevention of Migraine via Intravenous Eptinezumab Safety and efficacy-1) Trial
    Silberstein, S. D.
    Kudrow, D.
    Saper, J.
    Janelidze, M.
    Smith, T.
    Dodick, D. W.
    Chakhava, G.
    Wilks, K.
    Schaeffler, B.
    Cady, R.
    Hirman, J.
    Smith, J.
    HEADACHE, 2018, 58 (08): : 1298 - 1298
  • [10] Eptinezumab for the Prevention of Episodic Migraine Through 1 Year: Results from the Phase 3 PROMISE-1 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-1) Trial
    Saper, Joel
    Wilks, Kerri
    Chakhava, George
    Cady, Roger
    Schaeffler, Barbara
    Biondi, David
    Hirman, Joe
    Smith, Jeff
    NEUROLOGY, 2019, 92 (15)
12345